Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis
about
A balancing act: efflux/influx in mycobacterial drug resistance4'-Phosphopantetheinyl transferase PptT, a new drug target required for Mycobacterium tuberculosis growth and persistence in vivoIntensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial.Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis.Docking studies on novel analogues of 8 methoxy fluoroquinolones against GyrA mutants of Mycobacterium tuberculosis.Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.Metabolism of the anti-tuberculosis drug ethionamide by mouse and human FMO1, FMO2 and FMO3 and mouse and human lung microsomesImpact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time.Development of new antituberculous agents based on new drug targets and structure-activity relationship.
P2860
Q24644870-DC9D3C54-115D-4C31-99B5-701A806A98A1Q28484764-0C40E106-D41D-41D0-ACA5-8ACF4CF7B050Q30498213-DC18E82B-3146-4A2D-BC3D-1C334925B7A0Q33805878-83201EEF-1179-4806-BDE1-A48C9335D130Q34094873-26911DA1-325A-4FFF-A442-D19872664700Q34737143-1E9C3A17-4FAF-4AAC-8302-F7665D16F611Q35127770-5AFCD081-F77A-4CA9-97C3-1019005C35F7Q37060764-3FD7C5ED-D971-4DF0-9C0F-D0E56EF6BC6CQ37124036-04660D11-5058-4BCC-91A7-5D70154EED38Q37346929-E7B5BB8A-89CD-4B2B-B158-CCE8F4AC4030Q37619123-D5CA211A-4F7E-447F-985D-EC22D4B7549BQ40138610-8EC649B6-1468-4683-91DC-CAB7D1E83508
P2860
Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis
@ast
Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis
@en
Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis
@nl
type
label
Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis
@ast
Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis
@en
Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis
@nl
prefLabel
Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis
@ast
Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis
@en
Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis
@nl
P2860
P1476
Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis
@en
P2093
Mary Sklaney
Michael H Cynamon
P2860
P304
P356
10.1128/AAC.47.8.2442-2444.2003
P407
P577
2003-08-01T00:00:00Z